Several brokerages have updated their recommendations and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) in the last few weeks:
- 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $36.00 to $37.00. They now have an “outperform” rating on the stock.
- 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $23.00 to $25.00. They now have a “market perform” rating on the stock.
- 8/5/2026 – ACADIA Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
- 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Citizens Jmp from $35.00 to $36.00. They now have a “market outperform” rating on the stock.
- 7/29/2026 – ACADIA Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
- 7/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Bank of America Corporation. They now have a $14.50 price target on the stock.
- 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by BMO Capital Markets from $34.00 to $36.00. They now have an “outperform” rating on the stock.
- 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by Stifel Nicolaus from $24.00 to $25.00. They now have a “hold” rating on the stock.
- 7/7/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $29.00 to $36.00. They now have an “outperform” rating on the stock.
- 6/30/2026 – ACADIA Pharmaceuticals was downgraded by HC Wainwright from “buy” to “hold”.
- 6/30/2026 – ACADIA Pharmaceuticals had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a “buy” rating on the stock.
- 6/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $37.00 price target on the stock.
- 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $32.00 to $35.00. They now have a “buy” rating on the stock.
- 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $36.00. They now have a “buy” rating on the stock.
Insider Activity at ACADIA Pharmaceuticals
In other ACADIA Pharmaceuticals news, insider James Kihara sold 5,401 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total value of $114,393.18. Following the sale, the insider directly owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the sale, the executive vice president owned 18,994 shares in the company, valued at $496,313.22. The trade was a 46.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 26.20% of the company’s stock.
The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.
Featured Stories
- Five stocks we like better than ACADIA Pharmaceuticals
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
